Prostate cancer (PCa) is the second most common cancer in men. The Androgen Receptor (AR) is the major driver of PCa and the main target of therapy in the advanced setting. AR is a nuclear receptor that binds the chromatin and regulates transcription of genes involved in cancer cell proliferation and survival. In a study by Stelloo et al.
Prostate cancer (PCa) is the second most common cancer in men. The Androgen Receptor (AR) is the major driver of PCa and the main target of therapy in the advanced setting. AR is a nuclear receptor that binds the chromatin and regulates transcription of genes involved in cancer cell proliferation and survival. In a study by Stelloo et al. (1) we explored prostate cancer on the level of transcriptional regulation by means of Formaldehyde-Assisted Isolation of Regulatory Elements and Chromatin Immunoprecipitation coupled with massive parallel sequencing (FAIRE-seq and ChIP-seq, respectively). We employed these data for the assessment of differences in transcriptional regulation at distinct stages of PCa progression and to construct a prognostic gene expression classifier. Genomics data includes FAIRE-seq data from normal prostate tissue as well as primary, hormone therapy resistant and metastatic PCa. Furthermore, ChIP-seq data from primary and resistant PCa were generated, along with multiple input controls. The data are publicly available through NCBI GEO database with accession number GSE65478. Here we describe the genomics and clinical data in detail and provide comparative analysis of FAIRE-seq and ChIP-seq data.
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1. Experimental design, materials and methods
Clinical samples and experimental design
Fresh frozen tissue samples were obtained through postoperative needle biopsies targeting both tumor and normal areas of prostatectomy specimens at The Netherlands Cancer Institute (Amsterdam, The Netherlands). Tissue samples from androgen deprivation resistant tumors (from transurethral resection of the prostate (TURP)) and lymph node metastases were obtained from the Erasmus University Medical Center (Rotterdam, The Netherlands). Slides stained with hematoxylin and eosin (H&E) of the cases were reviewed by our pathologists. Clinical and pathological parameters of the selected patients are provided in Table 1 . Leftover anonymized tissue, which cannot be traced back to the patient and does not interfere with care and/or prognosis, and would have been discarded otherwise, has been used in accordance with the Code of Conduct of the Federation of Medical Scientific Societies in The Netherlands. NKI and Erasmus MC institutional medical ethics committees have approved the study. 
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Genomics Data j o u r n a l h o m e p a g e : w w w . e l s e v i e r . c o m / l o c a t e / g d a t a FAIRE-seq was performed on four normal samples, four primary, three therapy resistant tumors and three lymph node metastases ( Fig. 1) . Androgen Receptor ChIP-seq was carried out on four primary and three resistant tumors (Fig. 1 ).
Formaldehyde-assisted isolation of regulatory elements (FAIRE)
FAIRE was performed as previously described [2] . Briefly, fresh frozen tissues were cross-linked with 1% formaldehyde for 20 min. After washing, nuclei were isolated as described before [3] . Afterwards chromatin was sonicated, cleared by centrifugation and subjected to three consecutive phenol-chloroform-isoamyl alcohol (25:24:1) extractions. Reverse cross-linking was performed at 65°C overnight. Subsequently, samples were treated with RNase A and proteinase K and purified by using a PCR purification kit (Roche).
Chromatin immunoprecipitation (ChIP)
Chromatin immunoprecipitation was carried out as described before [3, 4] . 10 μg of AR-N20 (sc-618; Santa Cruz) antibody was used for immunoprecipitation, with 100 μl of Protein A magnetic beads (Invitrogen).
DNA sequencing
Libraries were prepared according to Illumina DNA Sample Kit instructions. Sequencing was performed on the Illumina HiSeq 2000 Genome Analyzer using 51-bp reads. Reads were aligned to the Human Reference Genome (assembly hg19, February 2009) using bwa 0.5.9.
Data analysis
Reads that map uniquely to the genome, with MAPQ quality score above 20, were used for the analysis. FAIRE-seq and ChIP-seq peaks were called with two algorithms, MACS 1.4 [5] and DFilter 1.0 [6] , against mixed input controls corresponding to each group. MACS was run with default parameters, except for p = 10 − 7 for
ChIP-seq data. DFilter was run with bs = 100, ks = 50 for FAIREseq data and bs = 50, ks = 30, refine, nonzero for ChIP-seq data. Peaks detected by both algorithms were used for further analysis. Sequencing read depths and number of called peaks can be found in Table 2 . FAIRE-seq, ChIP-seq data and clinical annotation of the samples that are deposited in NCBI GEO under accession number GSE65478.
For further analysis, a merged list of peaks present in all samples from each technique was generated. The number of peaks detected by FAIRE-seq was 25,797, while 20,703 peaks were detected by ChIP-seq. The AR binding sites had a median width of 350 bp and peak size did not vary strongly with the largest peak size of 1202 bp (Fig. 2A) . In contrast, FAIRE-seq peaks had a larger spread in size with a median size of 255 bp. The largest peak size of FAIRE-seq data was 2300 bp and a higher proportion of both small and large peaks was present (Fig. 2A) . The distance to the nearest transcription start site (TSS) was determined by the GREAT tool (http://great.stanford.edu/) [7] . The number of peaks within 5 kb from the nearest TSS was significantly higher in FAIRE-seq data as compared to ChIP-seq data and the number of peaks further than 50 kb from a TSS was higher in ChIP-seq data than in FAIRE-seq (p b 10 − 15 Fisher's exact; Fig. 2B-C) . This is in accordance with AR binding mainly distant enhancer elements [8] , while accessible regions detected by FAIRE-seq include not only enhancers, but also promoters [9] .
Conclusions
In conclusion, we provide a unique dataset of genome-wide epigenetic profiling of prostate cancer tissue from different stages of the disease. The dataset consists of two parts: accessible chromatin profiling by FAIRE-seq and genome-wide androgen receptor binding to DNA by ChIP-seq. We previously used this dataset to identify changes in transcriptional regulation in prostate cancer upon acquisition of resistance to hormonal therapy, as well as to derive a prognostic gene expression signature for prostate cancer [1] . 
